Cargando…

Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006

AIM: Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996–2006. BACKGROUND: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient to reduce or s...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Eduard J., Mandalia, Sundhiya, Lo, Gary, Sharott, Peter, Youle, Mike, Anderson, Jane, Baily, Guy, Brettle, Ray, Fisher, Martin, Gompels, Mark, Kinghorn, George, Johnson, Margaret, McCarron, Brendan, Pozniak, Anton, Tang, Alan, Walsh, John, White, David, Williams, Ian, Gazzard, Brian
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102104/
https://www.ncbi.nlm.nih.gov/pubmed/21633514
http://dx.doi.org/10.1371/journal.pone.0020200
_version_ 1782204349603119104
author Beck, Eduard J.
Mandalia, Sundhiya
Lo, Gary
Sharott, Peter
Youle, Mike
Anderson, Jane
Baily, Guy
Brettle, Ray
Fisher, Martin
Gompels, Mark
Kinghorn, George
Johnson, Margaret
McCarron, Brendan
Pozniak, Anton
Tang, Alan
Walsh, John
White, David
Williams, Ian
Gazzard, Brian
author_facet Beck, Eduard J.
Mandalia, Sundhiya
Lo, Gary
Sharott, Peter
Youle, Mike
Anderson, Jane
Baily, Guy
Brettle, Ray
Fisher, Martin
Gompels, Mark
Kinghorn, George
Johnson, Margaret
McCarron, Brendan
Pozniak, Anton
Tang, Alan
Walsh, John
White, David
Williams, Ian
Gazzard, Brian
author_sort Beck, Eduard J.
collection PubMed
description AIM: Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996–2006. BACKGROUND: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient to reduce or stabilize costs. 2NRTIs + NNRTI regimens are cost-effective regimens for first-line HAART, but these regimens have not been compared with first-line PI(boosted) regimens. METHODS: Times to first-line treatment failure and annual costs were calculated for first-line HAART regimens by CD4 count when starting HAART (2006 UK prices). Cost-effectiveness of 2NRTIs+NNRTI versus 2NRTIs+PI(boosted) regimens was calculated for four CD4 strata. RESULTS: 55% of 5,541 people living with HIV (PLHIV) started HAART with CD4 count ≤200 cells/mm3, many of whom were Black Africans. Annual treatment cost decreased as CD4 count increased; most marked differences were observed between starting HAART with CD4 ≤200 cells/mm3 compared with CD4 count >200 cells/mm3. 2NRTI+PI(boosted) and 2NRTI+NNRTI regimens were the most effective regimens across the four CD4 strata; 2NRTI+NNRTI was cost-saving or cost-effective compared with 2NRTI + PI(boosted) regimens. CONCLUSION: To ensure more effective and efficient provision of HIV services, 2NRTI+NNRTI should be started as first-line HAART regimen at CD4 counts ≤350 cell/mm3, unless specific contra-indications exist. This will increase the number of PLHIV receiving HAART and will initially increase population costs of providing HIV services. However, starting PLHIV earlier on cost-effective regimens will maintain them in better health and use fewer health or social services, thereby generating fewer treatment and care costs, enabling them to remain socially and economically active members of society. This does raise a number of ethical issues, which will have to be acknowledged and addressed, especially in countries with limited resources.
format Text
id pubmed-3102104
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31021042011-06-01 Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006 Beck, Eduard J. Mandalia, Sundhiya Lo, Gary Sharott, Peter Youle, Mike Anderson, Jane Baily, Guy Brettle, Ray Fisher, Martin Gompels, Mark Kinghorn, George Johnson, Margaret McCarron, Brendan Pozniak, Anton Tang, Alan Walsh, John White, David Williams, Ian Gazzard, Brian PLoS One Research Article AIM: Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996–2006. BACKGROUND: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient to reduce or stabilize costs. 2NRTIs + NNRTI regimens are cost-effective regimens for first-line HAART, but these regimens have not been compared with first-line PI(boosted) regimens. METHODS: Times to first-line treatment failure and annual costs were calculated for first-line HAART regimens by CD4 count when starting HAART (2006 UK prices). Cost-effectiveness of 2NRTIs+NNRTI versus 2NRTIs+PI(boosted) regimens was calculated for four CD4 strata. RESULTS: 55% of 5,541 people living with HIV (PLHIV) started HAART with CD4 count ≤200 cells/mm3, many of whom were Black Africans. Annual treatment cost decreased as CD4 count increased; most marked differences were observed between starting HAART with CD4 ≤200 cells/mm3 compared with CD4 count >200 cells/mm3. 2NRTI+PI(boosted) and 2NRTI+NNRTI regimens were the most effective regimens across the four CD4 strata; 2NRTI+NNRTI was cost-saving or cost-effective compared with 2NRTI + PI(boosted) regimens. CONCLUSION: To ensure more effective and efficient provision of HIV services, 2NRTI+NNRTI should be started as first-line HAART regimen at CD4 counts ≤350 cell/mm3, unless specific contra-indications exist. This will increase the number of PLHIV receiving HAART and will initially increase population costs of providing HIV services. However, starting PLHIV earlier on cost-effective regimens will maintain them in better health and use fewer health or social services, thereby generating fewer treatment and care costs, enabling them to remain socially and economically active members of society. This does raise a number of ethical issues, which will have to be acknowledged and addressed, especially in countries with limited resources. Public Library of Science 2011-05-25 /pmc/articles/PMC3102104/ /pubmed/21633514 http://dx.doi.org/10.1371/journal.pone.0020200 Text en Beck et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Beck, Eduard J.
Mandalia, Sundhiya
Lo, Gary
Sharott, Peter
Youle, Mike
Anderson, Jane
Baily, Guy
Brettle, Ray
Fisher, Martin
Gompels, Mark
Kinghorn, George
Johnson, Margaret
McCarron, Brendan
Pozniak, Anton
Tang, Alan
Walsh, John
White, David
Williams, Ian
Gazzard, Brian
Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
title Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
title_full Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
title_fullStr Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
title_full_unstemmed Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
title_short Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
title_sort cost-effectiveness of early treatment with first-line nnrti-based haart regimens in the uk, 1996-2006
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102104/
https://www.ncbi.nlm.nih.gov/pubmed/21633514
http://dx.doi.org/10.1371/journal.pone.0020200
work_keys_str_mv AT beckeduardj costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT mandaliasundhiya costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT logary costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT sharottpeter costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT youlemike costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT andersonjane costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT bailyguy costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT brettleray costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT fishermartin costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT gompelsmark costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT kinghorngeorge costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT johnsonmargaret costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT mccarronbrendan costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT pozniakanton costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT tangalan costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT walshjohn costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT whitedavid costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT williamsian costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT gazzardbrian costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006
AT costeffectivenessofearlytreatmentwithfirstlinennrtibasedhaartregimensintheuk19962006